Ado-trastuzumab emtansine usage and dosage

The recommended dose of Ado-trastuzumab emtansine is 3.6 mg/kg as an intravenous infusion every 3 weeks (21-day cycle). Do not administer trastuzumab in doses greater than 3.6 mg/kg. Patients with metastatic breast cancer (MBC) should receive treatment until disease progression or uncontrollable toxicity; patients with early-stage breast cancer (EBC) should receive a total of 14 cycles of treatment unless disease relapse or uncontrollable toxicity occurs.

If the patient's first infusion takes more than 90 minutesObserve the patient for fever, chills, or other infusion-related reactions during the infusion and for at least 90 minutes after the first dose. If the previous infusion is well tolerated, administer within 30 minutes. Observe the patient during and for at least 30 minutes after the infusion. However, if the patient develops adverse reactions after using Trastuzumab, the doctor will adjust the dose according to the adverse reactions. The first dose will be reduced to 3mg/kg, and the second dose will be reduced to 2.4mg/kg. If the patient needs to further reduce the dose, Trastuzumab treatment should be stopped. And after reducing the dose, do not increase the dose of trastuzumab.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.